Encapsulated Glioma — Trials

Encapsulated Glioma — Trials · CancerIndex

Clinical trials

Registered studies

328 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 116
Recruiting: 55
Ph III recruiting: 5
Growth YoY: —
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: 40.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (51)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05760586	Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma	approved for marketing	—	—	Day One Biopharmaceuticals, Inc.INDUSTRY	0	Aug 12, 2024	clinicaltrials

Data updated 22 days agoSource updated Aug 12, 2024source: clinicaltrials